Explicit|20|98|336..338|1,0,1,2,1,1,1,2,1|or|||or|||Expansion.Alternative.Disjunctive||||Ot|Comm|Null|Null|390..425|1,1;1,2;1,3;1,4|said Oncor President Stephen Turner|314..335|1,0,1,2,1,1,1,2,0|whether it has spread|Inh|Null|Null|Null||||339..388|1,0,1,2,1,1,1,2,2|whether there is a recurrence following treatment|Inh|Null|Null|Null|||||||||
Implicit|20|98||||443|2||so||Contingency.Cause.Result||||Wr|Comm|Null|Null||||210..388|1,0|The B/T gene rearrangement test is more accurate than existing tests for diagnosing the type of cancer, whether it has spread or whether there is a recurrence following treatment|Ot|Comm|Null|Null|390..425|1,1;1,2;1,3;1,4|said Oncor President Stephen Turner|443..581|2,1,1|the test initially will be used in conjunction with biopsies and other tests, but eventually might become the benchmark for tumor analysis|Ot|Comm|Null|Null|427..442|2,0;2,1,0;2,2|Mr. Turner said||||||
EntRel|20|98||||583|3|||||||||||||||427..581|2|Mr. Turner said the test initially will be used in conjunction with biopsies and other tests, but eventually might become the benchmark for tumor analysis||||||||583..673|3|Mr. Turner said the test will be shipped in 45 days to hospitals and clinical laboratories|||||||||||||
Explicit|20|98|842..849|4,1,1,1,1,2,2,2,0|because|||because|||Contingency.Cause.Reason||||Ot|Comm|Null|Null|677..765|4,0;4,1,0;4,2|Dr. Wyndham Wilson, a cancer treatment specialist at the National Cancer Institute, said|810..841|4,1,1,1,1,1;4,1,1,1,1,2,0;4,1,1,1,1,2,1;4,1,1,1,1,2,2,0;4,1,1,1,1,2,2,1|but isn't having a major impact|Inh|Null|Null|Null||||850..921|4,1,1,1,1,2,2,2,1|it is only occasionally useful in choosing the most effective treatment|Inh|Null|Null|Null|||||||||
Explicit|20|98|923..926|5,0,0|But|||but|||Comparison.Contrast.Juxtaposition||||Ot|Comm|Null|Null|1042..1057|5,1;5,2;5,3;5,4|Dr. Wilson said|842..921|4,1,1,1,1,2,2,2|because it is only occasionally useful in choosing the most effective treatment|Ot|Comm|Null|Null|677..765|4,0;4,1,0;4,2|Dr. Wyndham Wilson, a cancer treatment specialist at the National Cancer Institute, said|927..1040|5,0,1;5,0,2|the test may prove to be more sensitive in determining whether a tumor has spread or returned following treatment|Inh|Null|Null|Null|||||||||
Implicit|20|98||||1060|6||so||Contingency.Cause.Result||||Ot|Comm|Null|Null|1108..1115|6,0;6,2;6,3;6,4;6,5;6,6|he said|766..1040|4,1,1;5,0|the test is widely used in research centers but isn't having a major impact because it is only occasionally useful in choosing the most effective treatment.But the test may prove to be more sensitive in determining whether a tumor has spread or returned following treatment|Ot|Comm|Null|Null|677..765;1042..1057|4,0;4,1,0;4,2;5,1;5,2;5,3;5,4|Dr. Wyndham Wilson, a cancer treatment specialist at the National Cancer Institute, said Dr. Wilson said|1060..1105|6,1|We don't know yet how useful it's going to be|Inh|Null|Null|Null|||||||||
EntRel|20|98||||1301|8|||||||||||||||1119..1299|7|Oncor, a six-year-old developer of genetic medical tests, projects that the cancer test will help it to post its first-ever profit during the first quarter of 1990, Mr. Turner said||||||||1301..1443|8|The company will charge $35 for a test and projects about $2 million in revenue from the test during the first 12 months of marketing, he said|||||||||||||
